EyePoint Pharmaceuticals Inc (EYPT)
11.72
-0.34
(-2.82%)
USD |
NASDAQ |
Nov 04, 12:56
EyePoint Pharmaceuticals Enterprise Value: 365.18M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 365.18M |
| October 31, 2024 | 349.13M |
| October 30, 2024 | 333.07M |
| October 29, 2024 | 337.35M |
| October 28, 2024 | 368.39M |
| October 25, 2024 | 228.17M |
| October 24, 2024 | 231.39M |
| October 23, 2024 | 252.79M |
| October 22, 2024 | 295.07M |
| October 21, 2024 | 292.40M |
| October 18, 2024 | 311.13M |
| October 17, 2024 | 316.48M |
| October 16, 2024 | 323.44M |
| October 15, 2024 | 248.51M |
| October 14, 2024 | 264.03M |
| October 11, 2024 | 192.32M |
| October 10, 2024 | 160.74M |
| October 09, 2024 | 168.77M |
| October 08, 2024 | 173.59M |
| October 07, 2024 | 185.90M |
| October 04, 2024 | 181.61M |
| October 03, 2024 | 167.70M |
| October 02, 2024 | 159.14M |
| October 01, 2024 | 147.90M |
| September 30, 2024 | 147.36M |
| Date | Value |
|---|---|
| September 27, 2024 | 146.83M |
| September 26, 2024 | 151.64M |
| September 25, 2024 | 155.93M |
| September 24, 2024 | 166.09M |
| September 23, 2024 | 163.42M |
| September 20, 2024 | 196.60M |
| September 19, 2024 | 211.05M |
| September 18, 2024 | 196.60M |
| September 17, 2024 | 189.64M |
| September 16, 2024 | 192.85M |
| September 13, 2024 | 206.77M |
| September 12, 2024 | 194.99M |
| September 11, 2024 | 159.67M |
| September 10, 2024 | 149.50M |
| September 09, 2024 | 160.74M |
| September 06, 2024 | 146.29M |
| September 05, 2024 | 151.11M |
| September 04, 2024 | 167.16M |
| September 03, 2024 | 156.19M |
| August 30, 2024 | 198.74M |
| August 29, 2024 | 186.43M |
| August 28, 2024 | 191.78M |
| August 27, 2024 | 206.23M |
| August 26, 2024 | 217.47M |
| August 23, 2024 | 211.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-36.76M
Minimum
Dec 19 2022
1.126B
Maximum
Feb 12 2024
224.37M
Average
171.74M
Median
Nov 08 2019
Enterprise Value Benchmarks
| Cassava Sciences Inc | 1.050B |
| Adverum Biotechnologies Inc | -19.69M |
| Regenxbio Inc | 144.07M |
| Editas Medicine Inc | -39.11M |
| Apellis Pharmaceuticals Inc | 3.504B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.83M |
| Revenue (Quarterly) | 9.477M |
| Total Expenses (Quarterly) | 44.02M |
| EPS Diluted (Quarterly) | -0.58 |
| Gross Profit Margin (Quarterly) | 85.22% |
| Profit Margin (Quarterly) | -325.3% |
| Earnings Yield | -15.19% |
| Normalized Earnings Yield | -15.19 |